# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

C. Measurand: Benzodiazepines

D. Type of Test: Semi-quantitative and qualitative homogeneous enzyme immunoassay

E. Applicant: Ortho-Clinical Diagnostic

# F. Proprietary and Established Names:

VITROS Chemistry Products BENZ Reagent   
VITROS Chemistry Products Calibrator Kit 26   
VITROS Chemistry Products FS Calibrator 1   
VITROS Chemistry Products DAT Performance Verifiers I. II, III, IV, and V

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 2 . 3 1 7 0$ , Benzodiazepine Test System 21 CFR $\ S 8 6 2 . 3 2 0 0$ , Clinical Toxicology Calibrator 21 CFR $\ S 8 6 2 . 3 2 8 0 $ , Clinical Toxicology Control Material   
2. Classification: Class II (Reagent, Calibrator) Class I Reserved (Control)   
3. Product code: JXM; DKB; DIF   
4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use: VITROS Chemistry Products BENZ Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi-quantitative or qualitative determination of benzodiazepines (BENZ) in human urine using a cutoff of either $2 0 0 ~ \mathrm { { n g / m L } }$ or $3 0 0 ~ \mathrm { { n g / m L } }$ . Measurements obtained with the VITROS BENZ method are used in the diagnosis and treatment of benzodiazepines use or overdose.

The VITROS Chemistry Products BENZ assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result obtained with this assay. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.

VITROS Chemistry Products Calibrator Kit 26 is used to calibrate VITROS 5.1 FS Chemistry Systems for the qualitative or semi-quantitative measurement of the drugs of abuse.

VITROS Chemistry Products FS Calibrator 1: For in vitro diagnostic use only. VITROS Chemistry Products FS Calibrator 1 is used in conjunction with VITROS Chemistry Products Calibrator Kits to calibrate VITROS 5,1 FS Chemistry Systems

VITROS Chemistry Products DAT Performance Verifiers are assayed control used to monitor performance of urine drugs of abuse screening assays on VITROS 5,1 FS Chemistry Systems.

3. Special conditions for use statement(s): This device is for use by professional laboratory personnel. For in vitro diagnostic use only.

4. Special instrument requirements: Ortho-Clinical Diagnostics VITROS 5,1 FS Chemistry System

# I. Device Description:

The VITROS BENZ Reagent is a dual-chambered package containing ready-to-use liquid reagents that are used to detect benzodiazepines in urine. Sample, calibrators, and controls are automatically treated with surfactant (DAT Diluent 2) prior to addition of reagents. Treated sample is added to Reagent 1 containing antibody reactive to diazepam, glucose-6-phosphate and nicotinamide adenine dinucleotide $( \mathrm { N A D } ^ { + } )$ , followed by Reagent 2 containing diazepam labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH).

VITROS Chemistry Products Calibrator Kit 26 is prepared from human urine to which drugs of abuse, metabolites of drugs of abuse, organic salts, surfactants and preservative have been added.

VITROS Chemistry Products FS Calibrator 1 is prepared from sodium chloride and processed water. These products are used to calibrate VITROS 5,1 FS Chemistry Systems for the qualitative and semi-quantitative measurement of cocaine.

VITROS DAT Performance Verifiers I, II, III, IV & V are prepared from a human urine pool to which analytes, surfactant and preservative have been added. These are assayed controls used to monitor performance of the VITROS COCM Reagent on VITROS 5,1 FS Chemistry Systems.

The product labeling for the Calibrator Kit 26 and Performance Verifiers contain warnings regarding the presence of human sourced materials and recommend the use of Universal Precautions when handling these products.

# J. Substantial Equivalence Information:

1. Predicate device name(s): EMIT II Plus Benzodiazepine Assay Liquicheck Urine Toxicology Controls

2. Predicate 510(k) number(s): k993985; k022707

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the qualitativeand semi-quantitativeanalysis ofbenzodiazepines inhuman urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Liquid, ready to use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Homogeneous enzymeimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Sheep polyclonal</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>VITROS 5,1 FSChemistry Systems</td><td rowspan=1 colspan=1>Multiple automatedclinical chemistryanalyzers</td></tr><tr><td rowspan=1 colspan=1>Calibrators: Number oflevel</td><td rowspan=1 colspan=1>Six</td><td rowspan=1 colspan=1>Qualitative: Three ateach cutoff valueSemi-quantitative: Five</td></tr><tr><td rowspan=1 colspan=1>Controls: Number oflevels</td><td rowspan=1 colspan=1>Five</td><td rowspan=1 colspan=1>Two</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CSLI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples   
CLSI EP5-A: Evaluation of Precision Performance of Clinical Chemistry Devices   
CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures, A Statistical Approach   
CLSI EP7-P: Interference Testing in Clinical Chemistry   
CLSI EP17-A: Protocols for Demonstration, Verification and Evaluation of Limits of Detection and Quantitation   
CLSI EP12-A: User Protocols for Evaluation of Qualitative Test Performance

# L. Test Principle:

The VITROS BENZ assay is a homogeneous enzyme immunoassay that is performed using the VITROS Chemistry Products BENZ Reagent with the VITROS Chemistry

Products Calibrator Kit 26, VITROS Chemistry Products FS Calibrator 1, and VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent/DAT Diluent 2) on VITROS 5,1 FS Chemistry Systems.

The assay is based on competition between benzodiazepines in the treated urine sample and diazepam labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, therefore the concentration of benzodiazepines in the urine sample is directly proportional to measured enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide $( \mathrm { N A D } ^ { + } )$ to NADH, resulting in an absorbance change that is measured spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Imprecision was evaluated with human urine based quality control materials on the VITROS 5,1 FS Chemistry System following CLSI Protocol EP5 and CLSI protocol EP12.

Imprecision for BENZ: Semi-Quantitative   

<table><tr><td rowspan="2">System</td><td colspan="3">Conventional Units (ng/mL) and SI Units (μg/L)</td><td rowspan="2">Within Lab</td><td rowspan="2">No. Observ.</td><td rowspan="2">No. Days</td></tr><tr><td>Mean Conc.</td><td>Within Day SD*</td><td>Within Lab SD**</td></tr><tr><td rowspan="5">VITROS 5,1 FS</td><td>157</td><td>8.3</td><td>15.1</td><td>CV%** 9.6</td><td>84</td><td>22</td></tr><tr><td>233</td><td>10.1</td><td>20.5</td><td>8.8</td><td>84</td><td>22</td></tr><tr><td>264</td><td>12.8</td><td>19.1</td><td>7.2</td><td>82</td><td>22</td></tr><tr><td>397</td><td>17.2</td><td>31.3</td><td>7.9</td><td>82</td><td>22</td></tr><tr><td>626</td><td>37.2</td><td>58.0</td><td>9.3</td><td>84</td><td>22</td></tr></table>

\* Within Day imprecision was determined using one or two runs per day with two replicates per run. \*\* Within Lab imprecision was determined using a single lot of reagents with one analyzer and four calibrations.

Qualitative imprecision was assessed using test fluids targeted at $\pm 2 5 \%$ of each cutoff.

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Cutoff Level(ng/mL &amp;g/L)</td><td rowspan=1 colspan=1>Test Fluid at ±25% Cutoff</td><td rowspan=1 colspan=1>Number ofObservations</td><td rowspan=1 colspan=1>Number ofCorrectResults</td></tr><tr><td rowspan=4 colspan=1>VITROS 5,1 FS</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>84</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>82</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>84</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>82</td></tr></table>

# b. Linearity/assay reportable range:

The sponsor followed CLSI EP6-A in determining the linear range of their device. The low and high concentration pools were mixed to give 13 admixtures of intermediate BENZ concentrations. Three determinations of all pools were made together with three determinations each of VITROS Chemistry Products

DAT Performance Verifiers I, II, III, IV, and V. This experiment was performed three times, once with each of three VITROS BENZ Reagent lots on the VITROS 5,1 FS Chemistry System. A linear regression was performed and the results indicated acceptable linearity across the range of 33 to 869 $\mathrm { { n g / m L } }$ . This linearity determination in conjunction with determination of the limit of quantitation was used to establish the reportable range of the VITROS BENZ assay to be 85 to $8 0 0 ~ \mathrm { { n g / m L } }$ .

# Analytical Recovery of Semi-Quantitative Results

Eight admixtures were prepared from two human urine pools. The BENZ values for the admixtures were verified by GC/MS. Percent recovery was calculated using the concentration obtained by the VITROS Chemistry Products BENZ Assay versus the GC/MS value.

Recovery of Lormetazepam   

<table><tr><td rowspan=1 colspan=1>GC/MS(ng/mL)</td><td rowspan=1 colspan=1>VITROS BENZ Assay(ng/mL)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>661</td><td rowspan=1 colspan=1>642</td><td rowspan=1 colspan=1>97.1</td></tr><tr><td rowspan=1 colspan=1>557</td><td rowspan=1 colspan=1>539</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>465</td><td rowspan=1 colspan=1>454</td><td rowspan=1 colspan=1>97.6</td></tr><tr><td rowspan=1 colspan=1>364</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>103.9</td></tr><tr><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>288</td><td rowspan=1 colspan=1>102.4</td></tr><tr><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>199</td><td rowspan=1 colspan=1>104.9</td></tr><tr><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>111.0</td></tr><tr><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>97.8</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The assigned values for the calibrators and controls are traceable to the Cerilliant lormetazepam standard catalogue L-910 and are verified by GC/MS. Real time and accelerated stability studies were conducted; protocols and acceptance criteria were described and found to be acceptable. These studies support the manufacturer’s stability claims. Real time studies are ongoing.

# d. Detection limit:

The detection limit was determined according to protocol recommendations in CLSI EP-17 on three different lots of reagent and one instrument platform. The claimed lower limit for VITROS BENZ is $8 5 ~ \mathrm { n g / m L }$ .

e. Analytical specificity:

The specificity of the VITROS BENZ assay for various benzodiazepines and structurally similar compounds was estimated by generating a dose response curve for each of the compounds listed below. The quantity $( \mathrm { n g / m L } )$ of compound that produces a value equivalent to the lormetazepam quantity $( \mathrm { n g / m L } )$ at each cutoff value is listed below. The combined effects of more than one compound detected in a sample may cause levels lower than those listed below to produce a value approximately equivalent to or greater than the cutoff value.

Substances that Cross-react with BENZ   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Quantity(ng/mL)equivalent to200 ng/mL oflormetazepam</td><td rowspan=1 colspan=1>% cross-reactivity*</td><td rowspan=1 colspan=1>Quantity(ng/mL)equivalent to300 ng/mL oflormetazepam</td><td rowspan=1 colspan=1>% cross-reactivity*</td></tr><tr><td rowspan=1 colspan=1>nordiazepam</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>285.7</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>300.0</td></tr><tr><td rowspan=1 colspan=1>prazepam</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>222.2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>250.0</td></tr><tr><td rowspan=1 colspan=1>tetrazepam</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>190.5</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>217.4</td></tr><tr><td rowspan=1 colspan=1>ketazolam</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>185.2</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>211.3</td></tr><tr><td rowspan=1 colspan=1>diazepam</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>169.5</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>187.5</td></tr><tr><td rowspan=1 colspan=1>N-desalkyflurazepam</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>166.7</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>164.8</td></tr><tr><td rowspan=1 colspan=1>medazepam</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>166.7</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>164.8</td></tr><tr><td rowspan=1 colspan=1>a-hydroxyalprazolam</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>166.7</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>193.5</td></tr><tr><td rowspan=1 colspan=1>flurazepam</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>153.8</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>175.4</td></tr><tr><td rowspan=1 colspan=1>a-hydroxytriazolam</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>142.9</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>162.2</td></tr><tr><td rowspan=1 colspan=1>nitrazepam</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>137.9</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>142.9</td></tr><tr><td rowspan=1 colspan=1>flunitrazepam</td><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>131.6</td><td rowspan=1 colspan=1>215</td><td rowspan=1 colspan=1>139.5</td></tr><tr><td rowspan=1 colspan=1>alprazolam</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>129.0</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>150.0</td></tr><tr><td rowspan=1 colspan=1>temazepam</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>121.2</td><td rowspan=1 colspan=1>230</td><td rowspan=1 colspan=1>130.4</td></tr><tr><td rowspan=1 colspan=1>norfludiazepam</td><td rowspan=1 colspan=1>195</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>260</td><td rowspan=1 colspan=1>115.4</td></tr><tr><td rowspan=1 colspan=1>halazepam</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>274</td><td rowspan=1 colspan=1>109.5</td></tr><tr><td rowspan=1 colspan=1>clonazepam</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>89.3</td><td rowspan=1 colspan=1>408</td><td rowspan=1 colspan=1>73.5</td></tr><tr><td rowspan=1 colspan=1>clobazam</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>83.3</td><td rowspan=1 colspan=1>440</td><td rowspan=1 colspan=1>68.2</td></tr><tr><td rowspan=1 colspan=1>oxazepam</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>74.1</td><td rowspan=1 colspan=1>380</td><td rowspan=1 colspan=1>78.9</td></tr><tr><td rowspan=1 colspan=1>7-aminoflunitrazepam</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>650</td><td rowspan=1 colspan=1>46.2</td></tr><tr><td rowspan=1 colspan=1>N-desmethyldiazepam</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>490</td><td rowspan=1 colspan=1>61.2</td></tr><tr><td rowspan=1 colspan=1>demoxepam</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>550</td><td rowspan=1 colspan=1>54.5</td></tr><tr><td rowspan=1 colspan=1>bromazepam</td><td rowspan=1 colspan=1>422</td><td rowspan=1 colspan=1>47.4</td><td rowspan=1 colspan=1>749</td><td rowspan=1 colspan=1>40.1</td></tr><tr><td rowspan=1 colspan=1>chlordiazeopoxide</td><td rowspan=1 colspan=1>1230</td><td rowspan=1 colspan=1>16.3</td><td rowspan=1 colspan=1>2900</td><td rowspan=1 colspan=1>10.3</td></tr><tr><td rowspan=1 colspan=1>7-aminoclonazepam</td><td rowspan=1 colspan=1>1800</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>norchlordiazepoxide</td><td rowspan=1 colspan=1>1900</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>3750</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>oxazepam glucuronide</td><td rowspan=1 colspan=1>&gt;10,000</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&gt;10,000</td><td rowspan=1 colspan=1>&lt;3</td></tr><tr><td rowspan=1 colspan=1>lorazepam glucuronide</td><td rowspan=1 colspan=1>&gt;10,000</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&gt;10,000</td><td rowspan=1 colspan=1>&lt;3</td></tr></table>

\* The VITROS BENZ Assay cutoff value $\mathrm { ( n g / m L ) }$ divided by the amount of crossreactant $\mathrm { ( n g / m L ) }$ that produces a value equivalent to the cutoff value, multiplied by 100.

Interfering Substances:

Known Interfering Substances for BENZ   

<table><tr><td rowspan=1 colspan=1>Cutoff Value(ng/mL)</td><td rowspan=1 colspan=1>Interferent*</td><td rowspan=1 colspan=2>InterferentConcentration</td><td rowspan=1 colspan=1>Bias(ng/mL)**</td></tr><tr><td rowspan=7 colspan=1>200</td><td rowspan=1 colspan=1>desipramine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>330 μmol/L</td><td rowspan=1 colspan=1>+57</td></tr><tr><td rowspan=1 colspan=1>dextromethorphan</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>368μmol/L</td><td rowspan=1 colspan=1>+47</td></tr><tr><td rowspan=1 colspan=1>dicyclomine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>289μmol/L</td><td rowspan=1 colspan=1>+47</td></tr><tr><td rowspan=1 colspan=1>diethylpropion</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>487μmol/L</td><td rowspan=1 colspan=1>+61</td></tr><tr><td rowspan=1 colspan=1>ethacrynic acid</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>330μmol/L</td><td rowspan=1 colspan=1>+73</td></tr><tr><td rowspan=1 colspan=1>imipramine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>357μmol/L</td><td rowspan=1 colspan=1>+88</td></tr><tr><td rowspan=1 colspan=1>indomethacin</td><td rowspan=1 colspan=1>2.5 mg/dL</td><td rowspan=1 colspan=1>70μmol/L</td><td rowspan=1 colspan=1>+65</td></tr></table>

Known Interfering Substances for BENZ   

<table><tr><td rowspan=1 colspan=1>Cutoff Value(ng/mL)</td><td rowspan=1 colspan=1>Interferent*</td><td rowspan=1 colspan=2>InterferentConcentration</td><td rowspan=1 colspan=1>Bias(ng/mL)**</td></tr><tr><td rowspan=7 colspan=1></td><td rowspan=1 colspan=1>phenyltoloxamine</td><td rowspan=1 colspan=1>2.5 mg/dL</td><td rowspan=1 colspan=1>98 μmol/L</td><td rowspan=1 colspan=1>+76</td></tr><tr><td rowspan=1 colspan=1>phenylbutazone</td><td rowspan=1 colspan=1>0.5 mg/dL</td><td rowspan=1 colspan=1>324 μmol/L</td><td rowspan=1 colspan=1>+56</td></tr><tr><td rowspan=1 colspan=1>promethazine</td><td rowspan=1 colspan=1>2.5 mg/dL</td><td rowspan=1 colspan=1>20 μmol/L</td><td rowspan=1 colspan=1>+49</td></tr><tr><td rowspan=1 colspan=1>sertraline</td><td rowspan=1 colspan=1>0.5 mg/dL</td><td rowspan=1 colspan=1>16μmol/L</td><td rowspan=1 colspan=1>+51</td></tr><tr><td rowspan=1 colspan=1>tripelannamine</td><td rowspan=1 colspan=1>1.0 mg/dL</td><td rowspan=1 colspan=1>39μmol/L</td><td rowspan=1 colspan=1>+68</td></tr><tr><td rowspan=1 colspan=1>tripolidine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>359 μmol/L</td><td rowspan=1 colspan=1>+41</td></tr><tr><td rowspan=1 colspan=1>NaCl</td><td rowspan=1 colspan=1>1500mg/dL</td><td rowspan=1 colspan=1>207mmol/L</td><td rowspan=1 colspan=1>+46</td></tr><tr><td rowspan=12 colspan=1>300</td><td rowspan=1 colspan=1>desipramine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>330 μmol/L</td><td rowspan=1 colspan=1>+67</td></tr><tr><td rowspan=1 colspan=1>dextromethorphan</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>368μmol/L</td><td rowspan=1 colspan=1>+61</td></tr><tr><td rowspan=1 colspan=1>dicyclomine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>379μmol/L</td><td rowspan=1 colspan=1>+75</td></tr><tr><td rowspan=1 colspan=1>diethylpropion</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>487μmol/L</td><td rowspan=1 colspan=1>+61</td></tr><tr><td rowspan=1 colspan=1>doxylamine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>370μmol/L</td><td rowspan=1 colspan=1>+80</td></tr><tr><td rowspan=1 colspan=1>ethacrynic acid</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>330μmol/L</td><td rowspan=1 colspan=1>+80</td></tr><tr><td rowspan=1 colspan=1>imipramine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>357μmol/L</td><td rowspan=1 colspan=1>+107</td></tr><tr><td rowspan=1 colspan=1>indomethacin</td><td rowspan=1 colspan=1>5.0 mg/dL</td><td rowspan=1 colspan=1>140μmol/L</td><td rowspan=1 colspan=1>+72</td></tr><tr><td rowspan=1 colspan=1>phenyltoloxamine</td><td rowspan=1 colspan=1>2.5 mg/dL</td><td rowspan=1 colspan=1>98μmol/L</td><td rowspan=1 colspan=1>+63</td></tr><tr><td rowspan=1 colspan=1>phenylbutazone</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>324μmol/L</td><td rowspan=1 colspan=1>+70</td></tr><tr><td rowspan=1 colspan=1>sertraline</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>327μmol/L</td><td rowspan=1 colspan=1>+152</td></tr><tr><td rowspan=1 colspan=1>tripelannamine</td><td rowspan=1 colspan=1>1.0 mg/dL</td><td rowspan=1 colspan=1>399 µmol/L</td><td rowspan=1 colspan=1>+64</td></tr></table>

\* The degree of interference at concentrations other than those listed might not be predictable from these results. Other interfering substances may be encountered in the patient population. \*\* The bias is an estimate of the maximum difference observed.

f. Assay cut-off:

The stated cutoffs of this assay are either $2 0 0 \mathrm { n g / m L }$ or $3 0 0 ~ \mathrm { { n g / m L } }$ .

2. Comparison studies:

a. Method comparison with predicate device:

A total of 115 human urine samples were assayed using the VITROS Chemistry Products BENZ Reagent and GC/MS or LC/MS reference method for lormetazepam. Percent agreement was evaluated at assay cutoff values of 200 $\mathrm { { n g / m L } }$ and $3 0 0 \mathrm { n g / m L }$ .

GC/MS Reference Method Comparison for BENZ  

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>GC/MS or LC/MS Reference</td><td rowspan=1 colspan=3>%Agreement</td></tr><tr><td rowspan=1 colspan=2>Cutoff Value(ng/mL)</td><td rowspan=1 colspan=1>LowNegative</td><td rowspan=1 colspan=1>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Overall</td></tr><tr><td rowspan=3 colspan=1>200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;100 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)100-200 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)200-300 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;300 ng/mL</td><td rowspan=3 colspan=1>76.8</td><td rowspan=3 colspan=1>93.7</td><td rowspan=3 colspan=1>83.5</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr></table>

GC/MS Reference Method Comparison for BENZ  

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>GC/MS or LC/MS Reference</td><td rowspan=1 colspan=3>%Agreement</td></tr><tr><td rowspan=1 colspan=2>Cutoff Value(ng/mL)</td><td rowspan=1 colspan=1>LowNegative</td><td rowspan=1 colspan=1>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Overall</td></tr><tr><td rowspan=3 colspan=1>300</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;150 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)150-300 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)300-450 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;450 ng/mL</td><td rowspan=3 colspan=1>86.1</td><td rowspan=3 colspan=1>88.9</td><td rowspan=3 colspan=1>87.0</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td></tr></table>

Summary of Discordant Results: GC/MS or LC/MS   

<table><tr><td rowspan=1 colspan=1>CutoffValue(ng/mL)</td><td rowspan=1 colspan=1>VITROS BENZAssay(ng/mL)</td><td rowspan=1 colspan=1>Reference(ng/mL)</td></tr><tr><td rowspan=19 colspan=1>200</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>415 oxazepam &amp; 26 temazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>395 alprazolam, 21 alpha-OH-alpraolam, and 168 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1>184 alprazolam &amp; 5 alpha-OH-alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>237oxazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>284 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>101 alpha-OH-alprazolam &amp; 41 alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>303 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>90 oxazepam, 26 temazepam, &amp; 4 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>248</td><td rowspan=1 colspan=1>38 alprazolam and 64 alpha-OH-alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>155 oxazepam, 23 temazepam, &amp; 8 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>284 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>343 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>106 alpha-OH-alprazolam on GC/MS</td></tr><tr><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>90 oxazepam, 20 temazepam, &amp; 15 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>422</td><td rowspan=1 colspan=1>26 oxazepam &amp; 6 of alpha-OH-alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>237 oxazepam on GC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>71 alprazolam and 51 alpha-OH-alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>&lt; 75 on GC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>76 oxazepam on GC/MS</td></tr></table>

Summary of Discordant Results: GC/MS or LC/MS   

<table><tr><td rowspan=1 colspan=1>CutoffValue(ng/mL)</td><td rowspan=1 colspan=1>VITROS BENZAssay(ng/mL)</td><td rowspan=1 colspan=1>Reference(ng/mL)</td></tr><tr><td rowspan=15 colspan=1>300</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>415 oxazepam &amp;26 temazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>395 alprazolam, 21 alpha-OH-alpraolam, and 168 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>200 temazepam, 104 oxazepam, &amp; 42 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>169 oxazepam, 127 temazepam, &amp; 50 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>284 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>343 7-amino-clonazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>106 alpha-OH-alprazolam on GC/MS</td></tr><tr><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>211 oxazepam, 31 temazepam, &amp; 15 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>90 oxazepam, 20 temazepam, &amp; 15 nordiazepam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>422</td><td rowspan=1 colspan=1>26 oxazepam &amp; 6 of alpha-OH-alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>466</td><td rowspan=1 colspan=1>118 alpha-OH-alprazolam &amp; 38 alprazolam on LC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>&lt; 75 on GC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>76 oxazepam on GC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>237 oxazepam on GC/MS</td></tr><tr><td rowspan=1 colspan=1>&gt;RR</td><td rowspan=1 colspan=1>71 alprazolam and 51alpha-OH-alprazolam on LC/MS</td></tr></table>

A total of 115 human urine samples were assayed using the VITROS Chemistry Products BENZ Reagent and a commercially available immunoassay method, for benzodiazepine. Percent agreement was evaluated at assay cutoff values of $2 0 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ .

To challenge performance at the $2 0 0 \mathrm { n g / m L }$ cutoff value, 44 of the 115 samples tested had concentrations within $+ / - 5 0 \%$ of the cutoff value, 27 samples below the cutoff value and 17 above the cutoff value.

To challenge performance at the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff value, 39 of the 115 samples tested had concentrations within $+ / - 5 0 \%$ of the cutoff value, 30 samples below the cutoff value and 9 above the cutoff value.

Commercial Method Comparison for BENZ   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>Commercial Method**</td><td rowspan=1 colspan=3>%Agreement</td></tr><tr><td rowspan=1 colspan=2>Cutoff Value(ng/mL)</td><td rowspan=1 colspan=1>LowNegative</td><td rowspan=1 colspan=1>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>%AgreementNegative</td><td rowspan=1 colspan=1>%AgreementPosive</td><td rowspan=1 colspan=1>%AgreementOverall</td></tr><tr><td rowspan=3 colspan=1>200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;100 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)100-200 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)200-300 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;300 ng/mL</td><td rowspan=3 colspan=1>100.0</td><td rowspan=3 colspan=1>95.2</td><td rowspan=3 colspan=1>97.4</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>300</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;150 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)150-300 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)300-450 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;450 ng/mL</td><td rowspan=3 colspan=1>98.6</td><td rowspan=3 colspan=1>93.3</td><td rowspan=3 colspan=1>96.5</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>0</td></tr></table>

b. Matrix comparison:

Not applicable; this device is for use with urine only.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.